MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs[1].

MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs[1].

MK-6240 Precursor (6e) is the synthetic precursor of (18)F]-MK-6240. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs[1].

MK-6240 Precursor (6e) is the synthetic precursor of (18)F]-MK-6240. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs[1].

MK-6240 Precursor (6e) is the synthetic precursor of (18)F]-MK-6240. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs[1].

MK-6240 Precursor (6e) is the synthetic precursor of (18)F]-MK-6240. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs[1].

MK-6240 Precursor (6e) is the synthetic precursor of (18)F]-MK-6240. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs[1].

MK-7845 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 of 8.7 nM[1].

MK-8245 analog (compound 6) is a potent stearoyl-CoA desaturase (SCD) inhibitor with an IC50 of 7 nM for rat SCD. MK-8245 analog has antidiabetic and antidyslipidemic effects[1].

MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation[1][2][3].

MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation[1][2][3].

MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation[1][2][3].

MKI67 Human Pre-designed siRNA Set A contains three designed siRNAs for MKI67 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MKKS Human Pre-designed siRNA Set A contains three designed siRNAs for MKKS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MKLN1 Human Pre-designed siRNA Set A contains three designed siRNAs for MKLN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MKNK1 Human Pre-designed siRNA Set A contains three designed siRNAs for MKNK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mknk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mknk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mknk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mknk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

MKNK2 Human Pre-designed siRNA Set A contains three designed siRNAs for MKNK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mknk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mknk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mknk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mknk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

MKRN1 Human Pre-designed siRNA Set A contains three designed siRNAs for MKRN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MKRN2 Human Pre-designed siRNA Set A contains three designed siRNAs for MKRN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MKRN3 Human Pre-designed siRNA Set A contains three designed siRNAs for MKRN3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MKS1 Human Pre-designed siRNA Set A contains three designed siRNAs for MKS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MKX Human Pre-designed siRNA Set A contains three designed siRNAs for MKX gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ML 315 is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research[1].

ML 315 is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research[1].

ML 315 is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research[1].

ML 315 is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research[1].

ML2006a4 is an orally active inhibitor for SARS-CoV-2 main protease (Mpro) with IC50 in picomolare value. ML2006a4 is cell permeable and antiviral active, that inhibits replication in SARS-CoV-2 in cells Huh7.5.1-ACE2-TMPRSS2 (Huh7.5.1++) in picomolare level[1]

ML307 is a potent, sub-micromolar, first-in-class Ubc13 enzyme activity inhibitor with an IC50 of 781 nM. ML307 has the potential for immunomodulation and inflammation research[1].

MLANA Human Pre-designed siRNA Set A contains three designed siRNAs for MLANA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLC1 Human Pre-designed siRNA Set A contains three designed siRNAs for MLC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLEB-1934 is a DNA replication inhibitor as a potent metergoline analog and can be used for antibacterial research[1].

MLEC Human Pre-designed siRNA Set A contains three designed siRNAs for MLEC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLF1 Human Pre-designed siRNA Set A contains three designed siRNAs for MLF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLF2 Human Pre-designed siRNA Set A contains three designed siRNAs for MLF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLH1 Human Pre-designed siRNA Set A contains three designed siRNAs for MLH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLH3 Human Pre-designed siRNA Set A contains three designed siRNAs for MLH3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLIP Human Pre-designed siRNA Set A contains three designed siRNAs for MLIP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLK-IN-2 (Compound 9a) is a Mixed Lineage Kinase 3 (MLK3) inhibitor containing 3H-imidazole [4,5-b] pyridine structure. IC50 value is 6 nM. MLK-IN-2 can be used to study cancer and neurodegenerative diseases[1].

MLKL Human Pre-designed siRNA Set A contains three designed siRNAs for MLKL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLKL-IN-7 (compound 9) is a MLKL inhibitor, and shows anti-necroptosis activity in HT-29 cells with the IC50 of 148.4 nM[1].

MLLT1 Human Pre-designed siRNA Set A contains three designed siRNAs for MLLT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLLT10 Human Pre-designed siRNA Set A contains three designed siRNAs for MLLT10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MLLT11 Human Pre-designed siRNA Set A contains three designed siRNAs for MLLT11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.